Clinical Trials Logo

Hepatitis B Vaccines clinical trials

View clinical trials related to Hepatitis B Vaccines.

Filter by:
  • None
  • Page 1

NCT ID: NCT03408730 Completed - Clinical trials for Hepatitis B Vaccines

Lot-to-lot Consistency of Sci-B-Vac™ in Adults

Start date: December 14, 2017
Phase: Phase 3
Study type: Interventional

A Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults

NCT ID: NCT03393754 Completed - Clinical trials for Hepatitis B Vaccines

Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults

Start date: December 13, 2017
Phase: Phase 3
Study type: Interventional

This study is a double-blind randomized controlled trial designed to establish the non-inferiority of Sci-B-Vac® compared to Engerix-B® in adults ≥ 18 years old and the superiority of Sci-B-Vac® compared to Engerix-B® in ≥ 45 years old.

NCT ID: NCT02898922 Completed - Clinical trials for Hepatitis B Vaccines

Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C:An Open-label Control Study in China

Start date: June 2013
Phase: Phase 4
Study type: Interventional

Background Hepatitis B virus (HBV) co-infection in individuals with hepatitis C virus (HCV) can enhance the severity of hepatitis and the risks of liver cirrhosis and hepatocellular carcinoma (HCC). Hepatitis B vaccine is an effective measure to prevent HBV infection. Whether patients with HCV infection have non-protective antibody responses to hepatitis B vaccination more frequently than healthy subjects is still controversial and studies about cytokine response have been seldom reported. Methods Not-in-treatment patients with chronic HCV infection and 1:2 community/gender matched healthy control were obtained from a community-based screening. All participants received three doses of hepatitis B vaccine (20 μg HBsAg/ml/dose) on 0, 1 and 6 months schedule. Anti-HBs was tested 1 month after the third dose of vaccination and was compared between two groups. Spot-forming cells (SFCs) of interferon-γ (IFN-γ), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-6 (IL-6) produced by lymphocyte were tested by enzyme-linked immunospot (ELISPOT) and were compared between two groups.

NCT ID: NCT02797782 Recruiting - Clinical trials for Hepatitis B Vaccines

Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Nile Delta of Egypt

Start date: June 2016
Phase: N/A
Study type: Observational

More than two billion individuals have serological evidence of hepatitis B virus (HBV) infection worldwide. Of these, 240 million are chronic carriers and approximately 786,000 hepatitis B related deaths occur annually. Currently available hepatitis B vaccines are extremely safe and have an efficacy of >90 percent against all HBV serotypes and genotypes. Thus, HBV infection can potentially be eradicated through global vaccination. A positive immune response to the vaccine is defined as the development of hepatitis B surface antibody (anti-HBs) at a titer of >10 mIU/mL. Although anti-HBs titers decrease with time, the duration of protection is long. Protection has been estimated to persist for up to 22 years after the primary vaccination schedule. Protection from clinical disease, despite declining or even undetectable anti-HBs levels, is probably due to the priming of memory cells, which are capable of eliciting an anamnestic response when challenged. This is supported by the rapid increases in anti-HBs titers in previously vaccinated individuals who administered booster injections.